CAR T Cells: Second-Line Treatment Option for NHL? - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma? 01/13/2022 Results from three clinical trials have found that CAR T cells may be superior to standard treatments for patients with B-cell NHL that has not responded to treatment (refractory) or has returned after treatment (relapsed).

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892